Related Experiment Video
Updated: Jul 21, 2026
23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?
1WHO-UNAIDS HIV Vaccine Initiative, Health Technology and Pharmaceuticals, WHO, Geneva, Switzerland. esparzaj@unaids.org
Lancet (London, England)
|July 8, 2000
Summary
Developing an effective HIV-1 vaccine is crucial for controlling the AIDS pandemic. Increased research, clinical trials, and equitable distribution strategies are vital for global vaccine availability.
Area of Science:
- Immunology
- Public Health
- Vaccinology
Background:
- The development of an effective Human Immunodeficiency Virus type 1 (HIV-1) vaccine remains the most promising long-term strategy for controlling the global AIDS pandemic.
- While small-scale clinical trials for HIV-1 vaccines have been ongoing since 1987, large-scale Phase III efficacy trials have only recently commenced in the USA and Thailand.
Purpose of the Study:
- To emphasize the urgent need for increased research and development efforts for HIV-1 vaccines.
- To highlight the importance of planning for the equitable distribution and implementation of potential HIV-1 vaccines.
- To advocate for continued parallel development and assessment of diverse vaccine candidates.
Main Methods:
- Review of ongoing HIV-1 vaccine clinical trial progress, including the initiation of Phase III efficacy trials.
- Analysis of the timeline for initial results from current efficacy trials (within 2-3 years).
- Consideration of necessary strategies for vaccine deployment and accessibility.
Main Results:
- Initial results from the first Phase III HIV-1 vaccine efficacy trials are anticipated within the next 2-3 years.
- The study underscores the necessity of proactive planning for vaccine utilization upon successful efficacy demonstration.
Conclusions:
- Accelerated research and clinical trials are essential to ensure the future availability of an effective HIV-1 vaccine.
- Financial incentives for industry and robust mechanisms for equitable distribution, particularly in less-developed countries and Africa, are critical.
- Continued parallel development of multiple vaccine candidates is important to maximize the chances of success.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:51Vaccinations
Overview
01:26Sexually Transmitted Infections
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:21Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...